Experimental study of ultralow-dose antibodies to cyclophosphamide on cyclophosphamide myelotoxicity.
The possibility of using ultralow-dose cyclophosphamide for reducing the myelotoxicity of cyclophosphamide, injected in the maximum permissible dose, was studied in mice. Combined treatment by the cytostatic and its ultralow-dose preparation led to a lesser suppression of the erythroid, lymphocytic, and particularly granulocytic hemopoiesis stems. This effect is explained by stimulation of the secretory activity of hemopoiesis-inducing microenvironment and hence, of the functional activity of granulocytopoiesis under the effect of ultralow-dose cyclophosphamide.
Epstein
O I
OI
Institute of Pharmacology, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences, Tomsk, Russia. moffice@materiamedica.ru
Dygai
A M
AM
Sergeeva
S A
SA
Zhdanov
V V
VV
Khrichkova
T Y
TY
Stavrova
L A
LA
Zyuz'kov
G N
GN
Udut
E V
EV
Simanina
E V
EV
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism; D003520:Cyclophosphamide / Q000276:immunology* / Q000633:toxicity*; D015672:Erythroid Precursor Cells / Q000378:metabolism; D055014:Granulocyte-Macrophage Progenitor Cells / Q000378:metabolism; D006098:Granulocytes / Q000166:cytology / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects*; D008297:Male; D051379:Mice
D000906:Antibodies; D003520:Cyclophosphamide